Table 1.
Demographic and clinical characteristics of study participants: results are expressed as percentages for categorical variables and mean ± standard deviation for continuous data
| Variables | All patients (69) |
Fallers (26) |
Non-fallers (43) |
P-value |
|---|---|---|---|---|
| Sociodemographic characteristics | ||||
| Sex (% M) | 55.1 | 42.3 | 62.8 | 0.097 |
| Age (years) | 61.7 ± 13.3 | 58.3 ± 14.1 | 63.8 ± 12.6 | 0.151 |
| Weight (kg) | 80.3 ± 18.7 | 75.7 ± 18.6 | 83.1 ± 18.5 | 0.114 |
| Height (cm) | 166.2 ± 9 | 166 ± 9 | 166.3 ± 9 | 0.892 |
| BMI (kg * m−2) | 29.1 ± 6.4 | 27.6 ± 7 | 30 ± 5.9 | 0.144 |
| Clinical history | ||||
| Dialysis vintage (days) | 713 ± 714 | 732 ± 636 | 701 ± 765 | 0.465 |
| CCI (score) | 5.3 ± 2.2 | 5.1 ± 2.1 | 5.4 ± 2.3 | 0.639 |
| Primary renal disease (%) | ||||
| Diabetic nephropathy | 25 | 26.9 | 23.8 | 0.773 |
| Glomerulonephritis | 19.1 | 19.2 | 19 | 1.000 |
| Polycystic kidney | 8.8 | 0 | 14.3 | 0.075 |
| Renovascular or hypertensive | 8.8 | 0 | 14.3 | 0.075 |
| Other | 20.6 | 23.1 | 19 | 0.690 |
| Uncertain aetiology | 17.6 | 30.8 | 9.5 | 0.046 |
| Type of vascular access (%) | ||||
| Arteriovenous fistula | 64.7 | 61.5 | 66.7 | 0.667 |
| Central-venous | 35.3 | 38.5 | 33.3 | 0.667 |
| Inter-dialytic weight gain (kg) | 1.6 ± 1.2 | 1.6 ± 1 | 1.6 ± 1.4 | 0.923 |
| Ultrafiltration rate (mL/kg/h) | 6.5 ± 2.4 | 7.1 ± 2.5 | 6.1 ± 2.3 | 0.095 |
| HD treatment time (h) | 4.1 ± 0.5 | 4.1 ± 0.4 | 4.2 ± 0.5 | 0.395 |
| Prescribed medications | ||||
| Medications (n°) | 11.8 ± 3.4 | 12.4 ± 3.3 | 11.5 ± 3.5 | 0.262 |
| Beta blockers use (%) | 50 | 42.3 | 54.8 | 0.318 |
| ACE-inhibitors use (%) | 7.4 | 7.7 | 7.1 | 1.000 |
| Ca-channel blockers use (%) | 57.4 | 50 | 61.9 | 0.335 |
| AngII-receptor antagonists use (%) | 16.2 | 11.5 | 19 | 0.512 |
| Alpha blockers use (%) | 32.4 | 38.5 | 28.6 | 0.397 |
| Antihypertensive use (%) | 83.8 | 80.8 | 85.7 | 0.737 |
| > 1 antihypertensive use (%) | 51.5 | 42.3 | 57.1 | 0.234 |
| Opiates use (%) | 19.1 | 11.5 | 23.8 | 0.342 |
| Antidepressants use (%) | 33.8 | 50 | 23.8 | 0.027 |
| Diuretics use (%) | 33.8 | 23.1 | 40.5 | 0.141 |
| Laboratory values | ||||
| Hb (g/dL) | 11.2 ± 1.2 | 11 ± 1 | 11.2 ± 1.2 | 0.317 |
| CRP (mg/L) | 25.8 ± 45.4 | 37.6 ± 59.2 | 18.3 ± 32.7 | 0.027 |
| Bicarbonate (mmol/L) | 21.2 ± 3.2 | 21.5 ± 3.1 | 21.1 ± 3.4 | 0.546 |
| Na (mmol/L) | 139 ± 2.8 | 138.4 ± 3.3 | 139.4 ± 2.4 | 0.388 |
| K (mmol/L) | 4.6 ± 0.7 | 4.6 ± 0.7 | 4.6 ± 0.6 | 0.992 |
| Urea (mg/dL) | 16.4 ± 5.1 | 15.7 ± 6.1 | 16.7 ± 4.5 | 0.276 |
| Phosphate (mmol/L) | 1.5 ± 0.6 | 1.5 ± 0.6 | 1.5 ± 0.5 | 0.978 |
| PTH (ρmol/L) | 27.2 ± 32.1 | 28.9 ± 43.4 | 26.2 ± 23.1 | 0.586 |
| Albumin (g/L) | 37.1 ± 4.3 | 36.1 ± 5.2 | 37.7 ± 3.7 | 0.146 |
| Adjusted calcium (mmol/L) | 2.4 ± 0.1 | 2.3 ± 0.1 | 2.4 ± 0.1 | 0.511 |
| URR (%) | 71.1 ± 6.2 | 71.1 ± 7.7 | 71 ± 5.1 | 0.994 |
| Creatinine (μmol/L) | 638.1 ± 161.3 | 592 ± 175.7 | 666 ± 147.1 | 0.064 |
Abbreviations: BMI body mass index, CCI Charlson comorbidity index, HD haemodialysis, ACE angiotensin-converting enzyme, Ca calcium, AngII angiotensin II, Hb hemoglobin, CRP C-reactive protein, Na sodium, K potassium, PTH parathyroid hormone, URR urea reduction ratio